Treatment of Melanoma In Situ on Sun-Damaged Skin With Topical 5% Imiquimod Cream Complicated by the Development of Invasive Disease

Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up

“…It is possible that any inflammation was subclinical or that there is an alternative mechanism of action of imiquimod. In addition, although an inflammatory reaction seems predictive of treatment responsiveness, patients in our own series as well as a previously reported case raise the possibility of a partial response to imiquimod 15 …”

“…In addition, although an inflammatory reaction seems predictive of treatment responsiveness, patients in our own series as well as a previously reported case raise the possibility of a partial response to imiquimod. 15 In conclusion, we have presented our experience of LM treated with imiquimod. Many patients were treated more than 5 years ago and show no signs of persistent disease.…”

Recurrence of Lentigo Maligna and Development of Invasive Melanoma after Treatment of Lentigo Maligna with Imiquimod

“…Invasive melanoma has previously been reported to occur after use of imiquimod for melanoma in situ. This melanoma occurred during treatment with imiquimod 6 . Our patient developed invasive melanoma 24 months after initial topical treatment and then 11 months after his second treatment with imiquimod.…”

Treatment and follow-up of melanoma in situ in a geriatric patient that is a nonsurgical candidate

“…Kai et al 11 followed 18 patients who cleared on histology after using imiquimod treatment to evaluate the recurrence of lentigo maligna and found a 0% reoccurrence rate at 5 years. Fisher and Lang 12 treated an 87-year-old patient with melanoma in situ, which was confirmed with 13 pretreatment biopsies, with 5% imiquimod cream and during treatment the patient developed invasive melanoma. Other studies show the efficacy of imiquimod in the treatment of melanoma in situ and lentigo maligna to be 76% histologic and 78% clinical clearance with a reoccurrence rate of 2.3% 5,13 .…”